CN107771077B - 用于治疗轴突损伤的小白菊内酯及其衍生物 - Google Patents
用于治疗轴突损伤的小白菊内酯及其衍生物 Download PDFInfo
- Publication number
- CN107771077B CN107771077B CN201680032229.0A CN201680032229A CN107771077B CN 107771077 B CN107771077 B CN 107771077B CN 201680032229 A CN201680032229 A CN 201680032229A CN 107771077 B CN107771077 B CN 107771077B
- Authority
- CN
- China
- Prior art keywords
- parthenolide
- axonal
- nerve
- damage
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 44
- 230000007844 axonal damage Effects 0.000 title claims abstract description 42
- 229940069510 parthenolide Drugs 0.000 title claims description 191
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 title claims description 187
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 title claims description 171
- 230000003376 axonal effect Effects 0.000 claims abstract description 105
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- 108010032479 tyrosyltubulin carboxypeptidase Proteins 0.000 claims abstract description 31
- 239000003112 inhibitor Substances 0.000 claims abstract description 30
- 102000029749 Microtubule Human genes 0.000 claims abstract description 20
- 108091022875 Microtubule Proteins 0.000 claims abstract description 20
- 210000004688 microtubule Anatomy 0.000 claims abstract description 20
- 210000003497 sciatic nerve Anatomy 0.000 claims description 66
- 230000006378 damage Effects 0.000 claims description 60
- 210000003050 axon Anatomy 0.000 claims description 58
- 208000014674 injury Diseases 0.000 claims description 50
- 208000027418 Wounds and injury Diseases 0.000 claims description 49
- 230000008929 regeneration Effects 0.000 claims description 48
- 238000011069 regeneration method Methods 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 23
- 210000001328 optic nerve Anatomy 0.000 claims description 18
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- KHSCYOFDKADJDJ-NQLMQOPMSA-N Cynaropicrin Chemical compound OCC(=C)C(=O)O[C@H]1CC(=C)[C@@H]2C[C@H](O)C(=C)[C@@H]2[C@H]2OC(=O)C(=C)[C@H]12 KHSCYOFDKADJDJ-NQLMQOPMSA-N 0.000 claims description 14
- STQKFHDZSADKCG-UHFFFAOYSA-N cynaropicrin Natural products OC1CC2C(C3OC(=O)C(=C)C3C(CC2=C)OC(=O)C(=C)O)C1=C STQKFHDZSADKCG-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 13
- 239000000835 fiber Substances 0.000 claims description 12
- 230000009885 systemic effect Effects 0.000 claims description 11
- 208000010412 Glaucoma Diseases 0.000 claims description 10
- 210000003901 trigeminal nerve Anatomy 0.000 claims description 9
- 230000002638 denervation Effects 0.000 claims description 6
- 239000003889 eye drop Substances 0.000 claims description 6
- 229940012356 eye drops Drugs 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229940121981 Carboxypeptidase inhibitor Drugs 0.000 claims description 4
- 210000003792 cranial nerve Anatomy 0.000 claims description 3
- 210000001525 retina Anatomy 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000007432 Tubulin-tyrosine ligase Human genes 0.000 abstract description 10
- 108020005542 Tubulin-tyrosine ligase Proteins 0.000 abstract description 10
- 229940127389 Ligase Activators Drugs 0.000 abstract description 4
- 239000003981 vehicle Substances 0.000 description 53
- 210000002569 neuron Anatomy 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 33
- 210000005036 nerve Anatomy 0.000 description 31
- 102000001267 GSK3 Human genes 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 108060006662 GSK3 Proteins 0.000 description 27
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 27
- 238000011002 quantification Methods 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 238000002347 injection Methods 0.000 description 19
- 108090000704 Tubulin Proteins 0.000 description 17
- 102000004243 Tubulin Human genes 0.000 description 17
- 210000003169 central nervous system Anatomy 0.000 description 17
- -1 piperidin-1-yl) parthenolide Chemical compound 0.000 description 17
- 238000011084 recovery Methods 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 210000003594 spinal ganglia Anatomy 0.000 description 16
- 208000034656 Contusions Diseases 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 210000000578 peripheral nerve Anatomy 0.000 description 14
- 210000004087 cornea Anatomy 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 208000028389 Nerve injury Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000008764 nerve damage Effects 0.000 description 10
- 230000014511 neuron projection development Effects 0.000 description 10
- 230000001953 sensory effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000009519 contusion Effects 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- 150000004175 parthenolide derivatives Chemical class 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 210000000278 spinal cord Anatomy 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229930012538 Paclitaxel Natural products 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 229960001592 paclitaxel Drugs 0.000 description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 8
- 238000000540 analysis of variance Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 6
- 102000008763 Neurofilament Proteins Human genes 0.000 description 6
- 108010088373 Neurofilament Proteins Proteins 0.000 description 6
- 206010039670 Sciatic nerve injury Diseases 0.000 description 6
- 102100028051 Stathmin-2 Human genes 0.000 description 6
- 238000002266 amputation Methods 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 6
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 210000004126 nerve fiber Anatomy 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 210000005044 neurofilament Anatomy 0.000 description 6
- 230000000284 resting effect Effects 0.000 description 6
- 210000003994 retinal ganglion cell Anatomy 0.000 description 6
- 239000011435 rock Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- IYOZTVGMEWJPKR-VOMCLLRMSA-N 4-[(1R)-1-aminoethyl]-N-pyridin-4-yl-1-cyclohexanecarboxamide Chemical compound C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-VOMCLLRMSA-N 0.000 description 5
- 101000697510 Homo sapiens Stathmin-2 Proteins 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 229950006344 nocodazole Drugs 0.000 description 5
- 125000000810 parthenolide group Chemical group 0.000 description 5
- 238000010149 post-hoc-test Methods 0.000 description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 4
- 101100037543 Arabidopsis thaliana RLP55 gene Proteins 0.000 description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000006386 Myelin Proteins Human genes 0.000 description 4
- 108010083674 Myelin Proteins Proteins 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000005056 cell body Anatomy 0.000 description 4
- 239000000824 cytostatic agent Substances 0.000 description 4
- 230000001085 cytostatic effect Effects 0.000 description 4
- 101150090422 gsk-3 gene Proteins 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 4
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 4
- 210000005012 myelin Anatomy 0.000 description 4
- 208000019382 nerve compression syndrome Diseases 0.000 description 4
- 210000002241 neurite Anatomy 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 210000004116 schwann cell Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000007492 two-way ANOVA Methods 0.000 description 4
- 238000010153 Šidák test Methods 0.000 description 4
- UJNSFDHVIBGEJZ-CMRIBGNTSA-N (1S,2R,4R,7Z,11S,12S)-12-[(dimethylamino)methyl]-4,8-dimethyl-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-13-one Chemical compound CN(C)C[C@@H]1[C@@H]2CC\C(C)=C/CC[C@@]3(C)O[C@@H]3[C@H]2OC1=O UJNSFDHVIBGEJZ-CMRIBGNTSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 210000000020 growth cone Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 3
- 210000003007 myelin sheath Anatomy 0.000 description 3
- 210000000715 neuromuscular junction Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101001057320 Arabidopsis thaliana Methionine aminopeptidase 1B, chloroplastic Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000038624 GSKs Human genes 0.000 description 2
- 108091007911 GSKs Proteins 0.000 description 2
- 206010061431 Glial scar Diseases 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
- 206010021135 Hypovitaminosis Diseases 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000030401 vitamin deficiency disease Diseases 0.000 description 2
- OIWJREZAJZVGQN-BYPYZUCNSA-N (3R)-3,4-dihydroxy-2-methylidenebutanoic acid Chemical compound C=C([C@H](CO)O)C(=O)O OIWJREZAJZVGQN-BYPYZUCNSA-N 0.000 description 1
- OIWJREZAJZVGQN-SCSAIBSYSA-N (3S)-3,4-dihydroxy-2-methylidenebutanoic acid Chemical compound OC[C@@H](O)C(=C)C(O)=O OIWJREZAJZVGQN-SCSAIBSYSA-N 0.000 description 1
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000030768 Optic nerve injury Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108050008927 Stathmin-2 Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- LMGZGXSXHCMSAA-UHFFFAOYSA-N cyclodecane Chemical compound C1CCCCCCCCC1 LMGZGXSXHCMSAA-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001617 median nerve Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 239000012660 pharmacological inhibitor Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 108010008314 tyrosine-tubulin Proteins 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Abstract
Description
Claims (9)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15164307.9 | 2015-04-20 | ||
EP15164307.9A EP3085371A1 (en) | 2015-04-20 | 2015-04-20 | Parthenolide and its derivatives for use in the treatment of axonal damage |
PCT/EP2016/055118 WO2016169698A1 (en) | 2015-04-20 | 2016-03-10 | Parthenolide and its derivatives for use in the treatment of axonal damage |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107771077A CN107771077A (zh) | 2018-03-06 |
CN107771077B true CN107771077B (zh) | 2021-07-30 |
Family
ID=52991585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680032229.0A Active CN107771077B (zh) | 2015-04-20 | 2016-03-10 | 用于治疗轴突损伤的小白菊内酯及其衍生物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20180140574A1 (zh) |
EP (2) | EP3085371A1 (zh) |
JP (1) | JP6835738B2 (zh) |
CN (1) | CN107771077B (zh) |
WO (1) | WO2016169698A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3431491A1 (en) * | 2017-07-18 | 2019-01-23 | Centre National De La Recherche Scientifique | Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof |
WO2019108835A1 (en) | 2017-11-29 | 2019-06-06 | The Trustees Of Columbia University In The City Of New York | Delta-2-tubulin as a biomarker and therapeutic target for peripheral neuropathy |
EP3949960A1 (en) * | 2020-08-06 | 2022-02-09 | Ruhr-Universität Bochum | Compounds (in particular salotenolide) in the treatment of axonal damage |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1700596A1 (en) | 2005-03-09 | 2006-09-13 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons |
CN102579426A (zh) * | 2011-01-12 | 2012-07-18 | 韩颖 | 小白菊内酯作为血小板活化因子拮抗剂的用途 |
-
2015
- 2015-04-20 EP EP15164307.9A patent/EP3085371A1/en not_active Withdrawn
-
2016
- 2016-03-10 WO PCT/EP2016/055118 patent/WO2016169698A1/en active Application Filing
- 2016-03-10 CN CN201680032229.0A patent/CN107771077B/zh active Active
- 2016-03-10 JP JP2017554899A patent/JP6835738B2/ja active Active
- 2016-03-10 EP EP16709069.5A patent/EP3285761B1/en active Active
- 2016-03-10 US US15/567,823 patent/US20180140574A1/en not_active Abandoned
-
2019
- 2019-08-29 US US16/555,461 patent/US11298337B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3285761B1 (en) | 2021-10-13 |
EP3285761A1 (en) | 2018-02-28 |
JP6835738B2 (ja) | 2021-02-24 |
CN107771077A (zh) | 2018-03-06 |
US20190388388A1 (en) | 2019-12-26 |
JP2018515447A (ja) | 2018-06-14 |
US11298337B2 (en) | 2022-04-12 |
US20180140574A1 (en) | 2018-05-24 |
WO2016169698A1 (en) | 2016-10-27 |
EP3085371A1 (en) | 2016-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2742973C (en) | Use of low dosages of lipoic acid in the treatment of ocular disorders | |
US6489350B1 (en) | Methods for treating neuropathic pain using heteroarylmethanesulfonamides | |
EP2099468B1 (en) | Methods of use of trk receptor modulators | |
US11298337B2 (en) | Parthenolide and its derivative for use in the treatment of axonal damage | |
BRPI0612859A2 (pt) | macrolìdeo e respectivo uso | |
JPH10507743A (ja) | 薬剤投与のための方法と手段 | |
CN109908140A (zh) | 生物素治疗多发性硬化的用途 | |
KR20070116632A (ko) | 프로스타글란딘 F2a 유도체를 유효 성분으로서 함유하는망막신경세포 보호제 | |
US20160158166A1 (en) | Methods of reducing brain cell apoptosis | |
WO2015135306A1 (zh) | 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物 | |
KR20060127843A (ko) | 가령 황반 변성 치료제 | |
AU2018210241A1 (en) | Therapeutic and neuroprotective peptides | |
El Baha et al. | Anatomical and functional outcomes of vitrectomy with/without intravitreal methotrexate infusion for management of proliferative vitreoretinopathy secondary to rhegmatogenous retinal detachment | |
KR20200101948A (ko) | 신경계 질환 치료제 | |
Antcliff et al. | The maintenance of per-operative mydriasis in phacoemulsification with topical diclofenac sodium | |
US20210379146A1 (en) | Method to restore or improve cognitive functions | |
KR20220079621A (ko) | 척수 손상의 치료 및/또는 재수초화를 위한 펩타이드의 전신 투여 | |
EP2842557A1 (en) | Mildronate in ophthalmic disorders | |
EP3949960A1 (en) | Compounds (in particular salotenolide) in the treatment of axonal damage | |
JP2023042650A (ja) | 眼科用剤 | |
EP2131651B1 (en) | Topical corneal analgesia using neurotensin receptor agonists | |
KR20230147163A (ko) | 안구 병태에 대한 단백질-기반 요법 | |
Schwartz et al. | Optic nerve disease and injury: Prospects for induction of regeneration | |
WO2014055054A1 (ru) | Применение 1-адамантилетилокси-з-морфолино - 2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора | |
Nieto-Sampedro | Neural plasticity and central nervous system lesion repair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190916 Address after: Bochum Applicant after: RUHR-UNIVERSITAT BOCHUM Address before: Dusseldorf Applicant before: HEINRICH HEINE UNIVERSITAT DUSSELDORF |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240207 Address after: Cologne, Germany Patentee after: UNIVERSITAT ZU KOLN Country or region after: Germany Address before: Bochum Patentee before: RUHR-UNIVERSITAT BOCHUM Country or region before: Germany |
|
TR01 | Transfer of patent right |